Browse Studies — Arctuva

Phase 1

Small Cohort, Off Label Treatment Assessing the Safety and Tolerability of NMN in DHDDS-Congenital Disorder of Glycosylation (DHDDS-CDG)

The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals wit…

DHDDS-Congenital Disorder of GlycosylationDHDDS-CDGCongenital Disorder of Glycosylation

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Eva Morava-KoziczNCT07572825

Phase 2

Evaluation of Efficacy and Safety of D-galactose Supplementation in SLC35A2-CDG, a Disorder of Hypogalactosylation

This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-…

SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Eva Morava-KoziczNCT05402384

Phase 2

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Crossover, Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects With Phosphoglucomutase 1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG)

This is a clinical trial to evaluate the efficacy of AVTX-801 (D-galactose) on the clinical manifestations of PGM1-CDG in participants currently taking D-galac…

PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Eva Morava-KoziczNCT05402332